Pancreatic cancer pill shown to nearly double overall survival time, drug company says

(NewsNation) — A pancreatic cancer drug is showing promising signs of a possible breakthrough after a clinical trial found it nearly doubled the length of survival among patients.

In a press release Monday, Revolution Medicines shared the findings of its Phase 3 clinical trial, which evaluated the drug Daraxonrasib in patients with metastatic pancreatic ductal adenocarcinoma who had been previously treated.

The company reports the drug, taken orally once a day, showed “clinically meaningful improvements” in progression-free survival and overall survival compared with standard-of-care cytotoxic chemotherapy delivered intravenously. Specifically, the drug showed a median overall survival of 13.2 months compared to 6.7 months for........

© The Hill